77 results about "Oral suspensions" patented technology

An oral suspension pharmaceutical composition is disclosed for water soluble salts of arylalkanoic acid (NSAID) drugs such as ibuprofen and naproxen. When mixed with glyceryl esters such as glyceryl caprate / caprylate and water, the resulting combination forms a “liquid scaffold” structure that reliably enables the suspension of significant quantities of said arylalkanoic acid drugs. For example, suspensions containing 25% w / w arylalkanoic acid may be obtained using the aforementioned combination. Suspensions comprising further pharmaceutically active agents, in addition to said arylalkanoic acids, may also be prepared. Also disclosed is a binary blend of glyceryl caprate / caprylate and the sodium salt of ibuprofen and a ternary blend of glyceryl caprate / caprylate and the potassium salt of ibuprofen.

The present invention provides oral formulations of particles of an active pharmaceutical ingredient, such as gepodasine or a pharmaceutically acceptable salt thereof, which are rapidly dispersed in water, or oral formulations comprising particles of an active pharmaceutical ingredient. The particles form palatable oral suspensions in solution, taste good, and are particularly useful for pediatric or difficult-to-swallow patient populations.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

The present invention relates to the field of pharmaceutical preparations, and in particular, to a sevelamer carbonate dry suspension and a preparation method thereof. In the sevelamer carbonate dry suspension, the dosage of the suspending agent is 0.13 - 0.33% of the total mass, the dosage of the flocculant is 0.05 - 0.39% of the total mass, the dosage of lactulose is 72.53 - 86.90% of the total mass, the dosage of the flavoring agent is 0.34 - 0.72% of the total mass, and the dosage of the sevelamer carbonate crude drug is 12.51 - 26.20% of the total mass. This sevelamer carbonate dry suspension not only has excellent dispersibility, but also can improve its gastrointestinal side effects.

The present disclosure provides novel methods and compositions for the use of Mariobavir in the treatment of pediatric and teenager patient populations. The present disclosure also provides compositions of Maripasvir in powder form for oral suspensions, which are useful in patients who are difficult to swallow pills, including pediatric and teenager patient populations.

The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of the container comprising the suspension. Also provided is a method of preparing the formulation and treating sickle cell anemia in pediatric patients.

A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.

An oral formulation of granules of an active ingredient such as gepotidacin or a pharmaceutically acceptable salt thereof that rapidly disperses in water, or an oral formulation comprising such granules. Such granules provide an oral suspension with good mouthfeel and palatability. This oral suspension is particularly useful for pediatric patient populations or patient populations with difficulty swallowing.

An oral formulation of, or comprising, granules of active pharmaceutical ingredient(s), such as gepotidacin or a pharmaceutically acceptable salt thereof, which disperse rapidly in water are presented. The granules generate a palatable oral suspension in solution with good mouthfeel and are particularly useful for the paediatric or hard-of-swallowing patient population.

The invention discloses application of hydrotalcite and an ursodesoxycholic acid oral suspension composition, a suspension is composed of two parts, namely a drug-loaded pellet and an inactive particle, the drug-loaded pellet is composed of a drug-loaded pellet core and a taste-masking coating layer, and the taste-masking coating layer comprises zein, hydrotalcite, an anti-sticking agent and a plasticizer; the inactive particles comprise a filling agent, a suspending aid and essence. The drug-loaded pellet of the ursodesoxycholic acid oral suspension composition is composed of a drug-loaded pellet core and a taste-masking coating layer, ursodesoxycholic acid is contained in the drug-loaded pellet core, and hydrotalcite serving as a pore-foaming agent is contained in the taste-masking coating layer. Therefore, when the composition medicine is taken, whether the film-forming material zein or the pore-foaming agent is not dissolved in water during taking, and after the composition medicine reaches the stomach, hydrotalcite can generate neutralization reaction with gastric acid to play a role of the pore-foaming agent, so that quick release of the composition medicine is ensured.

The present invention discloses a sodium zirconium cyclosilicate oral suspension and a preparation method thereof, which comprise the following components in mass percentages: 10-30% of sodium zirconium cyclosilicate, 0.1-2.0% of cellulose, 0.01-0.30% of suspending agent, 0-10% of flavoring agent, 0-1.0% of preservative, and purified water; the suspending agent is a mixture of xanthan gum and locust bean gum. The potassium ion exchange capacity of the sodium zirconium cyclosilicate oral suspension of the present invention is equivalent to that of the commercially available powder and has good dispersion stability.

Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder / filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

The invention belongs to the technical field of pharmaceutical preparations, and relates to an anhydroicaritin nanocrystal oral suspension and a preparation method thereof. The oral suspension contains anhydroicaritin nanocrystals, a suspending aid, a surfactant, a buffer salt system and other pharmaceutically acceptable auxiliary materials. By optimizing the surfactant system and the pH range, the stability of the anhydroicaritin is effectively improved. The problem of long-term stability of a nanocrystalline oral suspension preparation prepared from anhydroicaritin is solved. According to the prescription, the dissolution speed of the medicine is increased, the bioavailability is improved, and the preparation method is easy to operate, stable in process and suitable for industrial production.

The invention relates to an azilsartan and amlodipine besylate oral suspension and a preparation method thereof. The azilsartan and amlodipine besylate oral suspension takes azilsartan and amlodipine besylate as active ingredients, xanthan gum and croscarmellose sodium as suspending aids, and water and glycerol as solvents; the mass ratio of xanthan gum to croscarmellose sodium is (20-30): (5-8). The compound of the croscarmellose sodium and the xanthan gum is used as a suspending aid, so that the azilsartan and the amlodipine besylate in the oral suspension can be ensured to be dispersed in colloid, cannot settle and gather, and are high in stability. When the suspension is taken, the suspension is convenient for adult patients with swallowing difficulty to use, the accuracy of administration dosage is ensured, the safety and effectiveness of the medicine are improved, and the problems of high viscosity and caking caused by long-time placement of a common suspension are solved.

Powder composition for oral suspension comprising a two phase powder mixture, where the first phase is in powder form comprising a Proton Pump Inhibitor (e.g. omeprazole) or pharmaceutically acceptable salts thereof in an amount of 0.01-7.5 % by weight, at least one diluent (e.g. mannitol), a first buffering agent (e.g. sodium hydrogen carbonate), a binding agent (e.g. xanthan gum), and the second phase is in powder form comprising a second buffering agent, a viscosity enhancer (e.g. sodium alginate) in the range 0.0010 %w / w to 2.0 wt.%, at least one diluent; at least one preservative (e.g. sodium benzoate, sodium methyl para hydroxy benzoate), a diluent, and an excipient (e.g. a flavour). Preferably, the second buffering agent is a carbonate or hydrogen carbonate. Preferably, the D50 of the omeprazole, if present, is 1.5-5.5 microns. The composition may be used in the treatment of erosive oesophagitis, gastroesophageal reflux, gastric ulcers etc.

This document discloses rivaroxaban tablets for oral suspension formulation for oral administration. Also disclosed is a method for preparing rivaroxaban tablets for oral suspension and a method of treating diseases.

The present invention relates to a powder for an edaravone oral suspension dosage form. The invention also relates to providing patient compliant, economical and technically advanced dosage forms over existing dosage forms. In addition, compared with the prior art, the patient compliance edaravone preparation prepared according to the invention is proved to be higher in solubility and stability. In addition, the present invention also provides a powder composition for oral suspension prepared by an improved method that is relatively simple, easy for commercial production, and replicable in function.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

The present application belongs to the technical field of pharmaceutical analysis, and particularly relates to a kind of analytical method for determining genetic toxic impurities in nilotinib composition.The present application has good specificity, simple operation, high sensitivity, low cost, and is suitable for frequent detection in mass production, etc., for determining impurity A in compositions such as nilotinib oral suspension, nilotinib dry suspension or nilotinib capsules.The method can effectively separate the nilotinib impurity A peak from its adjacent impurity peak, and solve the problem of easy damage of the chromatographic column during the determination of nilotinib impurity A.

This invention discloses an oral suspension of an anti-tuberculosis drug and its preparation method. The oral suspension contains an anti-tuberculosis drug, a suspending agent, a surfactant, an antibacterial agent, an antioxidant, a flavoring agent, and a pH adjuster. It has technical advantages such as stable physical and chemical properties, uniform content, and easy long-term storage.

The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg / mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.

The invention discloses a stable eplerenone oral suspension and a preparation method thereof. According to the oral suspension, a buffer pair pH regulator is adopted to regulate the pH value of the oral suspension of the system to 3.0-5.0, so that the stability of the product in the storage process is maintained. Meanwhile, compared with eplerenone tablets, the eplerenone oral suspension provided by the invention has the advantages that the absorption is faster, the in-vivo exposure of the medicine is larger, the bioavailability is obviously improved by about 50%, and a reliable high-stability and high-bioavailability eplerenone oral suspension preparation scheme is provided clinically.

The present invention provides a liquid composition for oral administration comprising an effective amount of hydroxyurea. The present invention also discloses a liquid formulation in the form of a ready-to-use oral suspension which remains stable at room temperature when dispensed, stored, even after the container containing the suspension is reopened. Also provided is a method of preparing the formulation and treating sickle cell anemia in a child patient.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a solifenacin succinate taste-masking composition and a preparation method thereof. Comprising solifenacin succinate and an auxiliary material for preparing the oral suspension, the auxiliary material comprises polacrilin potassium, and the mass ratio of solifenacin succinate to polacrilin potassium is (0.5-2): (1-4); the particle size condition of the polacrilin potassium is as follows: D90 is 110-180 [mu] m, and D50 is 30-80 [mu] m. The solifenacin succinate taste-masking composition provided by the invention not only has a good taste-masking effect, but also can improve the dissolution curve of solifenacin succinate, so that the medication compliance of a patient is improved, side effects are reduced, and the curative effect of solifenacin succinate is further ensured.

The present invention relates to a pharmaceutical composition comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizers in the form: A) an aqueous solution for intravenous administration comprising a sodium salt or lysine salt of ibuprofen, acetaminophen and preferably one or more cyclodextrins; or B) an aqueous solution for intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins; or C) a composition for oral administration comprising acetaminophen and cyclodextrin wherein the composition is in the form of i) an effervescent tablet or effervescent granule, or ii) an oral suspension or syrup or oral solution, or iii) a soft capsule.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to anhydroicaritin nanocrystalline oral suspension and a preparation method thereof. The oral suspension disclosed by the invention contains anhydroicaritin nanocrystals, a space protecting agent, a surfactant, a preservative, a pH regulator and other pharmaceutically acceptable auxiliary materials. Compared with the prior art, the problem that the stability is poor after the anhydroicaritin is prepared into the nanocrystal is solved; particle size distribution is uniform, and aggregation and layering phenomena are avoided; related substances are controllable, the safety is higher, the taste is good, the dosage can be accurately divided according to the body weight, and children, old people and patients with dysphagia can take the medicine conveniently. The oral suspension is simple in preparation method and suitable for industrial production.

The invention discloses a lamotrigine oral suspension and a preparation method thereof, the lamotrigine oral suspension is composed of lamotrigine and other pharmaceutic adjuvants, the pharmaceutic adjuvants are composed of a suspending aid, a wetting agent, a bacteriostatic agent, a flavoring agent, a defoaming agent, a pH regulator and a solvent, and the wetting agent is hydroxypropyl methylcellulose, glycerin, Tween 80 and the like. According to the invention, the suspending aid is adopted to increase the liquid viscosity and improve the stability of the suspension, and the wetting agent is adopted to improve the hydrophobicity of API, so that the stability and redispersibility of the suspension are improved, and the preparation process is simple and suitable for industrial mass production.

This application relates to the field of medicine, and specifically discloses a fexofenadine hydrochloride oral suspension and a preparation method thereof. The oral suspension includes an active ingredient and excipients. The active ingredient is fexofenadine hydrochloride, and the excipients at least include a flavoring agent, a suspending agent, a preservative, and a dispersing aid. The suspending agent includes one or both of sodium carboxymethylcellulose and hydroxypropyl methylcellulose; the dispersing aid is a mixture of polyvinylpyrrolidone and gelatinized modified microcrystalline cellulose; the preparation method includes the following steps: S1. Add water, then add a buffer solution, stir to dissolve, add the dispersing aid, and then add fexofenadine hydrochloride, and stir to obtain raw material A; S2. Mix water and the preservative to obtain raw material B; S3. Add the suspending agent to raw material A, then add raw material B, mix and stir, add the flavoring agent, and add the remaining water to make up the volume to obtain the product. This application has the advantage that the prepared fexofenadine hydrochloride oral suspension has good redispersibility.

The invention relates to the technical field of medical medicines, in particular to a taste-masking oral suspension containing 3-boryl-L-phenylalanine and a preparation method of the taste-masking oral suspension. Each 100 mL of the taste-masking oral suspension is prepared from the following components: 4 to 6 g of 3-boryl-L-phenylalanine, 8.5 to 17.5 g of beta-cyclodextrin, 0.08 to 0.12 g of stevioside, 0.03 to 0.08 g of lemon essence, 0.25 to 0.35 g of xanthan gum and 0.08 to 0.12 g of potassium sorbate. On the basis of an intermolecular hydrophobic interaction principle, a benzene ring bitter group of 3-BPA is specifically included by utilizing a hydrophobic cavity of beta-cyclodextrin, so that taste perception is reduced; natural stevioside (free of heat and dental caries risk) and lemon essence (capable of covering residual peculiar smell) form a synergistic taste-masking system, and the synergistic taste-masking system is matched with a xanthan gum suspending aid to prepare a uniform suspension; the preparation has the core advantages that the characteristic of high water solubility (125 g / L) of 3-BPA is fully utilized, the preparation does not need to add any solubilizer, taste optimization, stability improvement and swallowing convenience adaptation are synchronously realized, and three core requirements of'curative effect, safety and compliance 'of medication for children are considered.